Cardax Inc Stock Analysis
| CDXI Stock | USD 0.0001 0.00 0.00% |
Cardax Inc holds a debt-to-equity ratio of -1.227. With a high degree of financial leverage come high-interest payments, which usually reduce Cardax's Earnings Per Share (EPS).
Given that Cardax's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Cardax is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Cardax to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Cardax is said to be less leveraged. If creditors hold a majority of Cardax's assets, the Company is said to be highly leveraged.
Cardax Inc is overvalued with Real Value of 8.4E-5 and Hype Value of 1.0E-4. The main objective of Cardax pink sheet analysis is to determine its intrinsic value, which is an estimate of what Cardax Inc is worth, separate from its market price. There are two main types of Cardax's stock analysis: fundamental analysis and technical analysis.
The Cardax pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Cardax's ongoing operational relationships across important fundamental and technical indicators.
Cardax |
Cardax Pink Sheet Analysis Notes
The company recorded a loss per share of 7.08. Cardax Inc last dividend was issued on the 15th of January 2020. The entity had 1:200 split on the 15th of January 2020. Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.The quote for Cardax Inc is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Cardax Inc please contact the company at 808 457 1400 or go to https://www.cardaxpharma.com.Cardax Inc Investment Alerts
| Cardax Inc generated a negative expected return over the last 90 days | |
| Cardax Inc has some characteristics of a very speculative penny stock | |
| Cardax Inc has a very high chance of going through financial distress in the upcoming years | |
| Cardax Inc currently holds 1000 K in liabilities. Cardax Inc has a current ratio of 0.09, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cardax until it has trouble settling it off, either with new capital or with free cash flow. So, Cardax's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cardax Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cardax to invest in growth at high rates of return. When we think about Cardax's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 538.95 K. Net Loss for the year was (5.06 M) with profit before overhead, payroll, taxes, and interest of 342.82 K. | |
| Cardax Inc currently holds about 61.71 K in cash with (1.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Cardax Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 161. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cardax's market, we take the total number of its shares issued and multiply it by Cardax's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
Cardax Inc technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cardax Inc Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Cardax middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Cardax Inc. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Cardax Outstanding Bonds
Cardax issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cardax Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cardax bonds can be classified according to their maturity, which is the date when Cardax Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| CARDINAL HEALTH INC Corp BondUS14149YAW84 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| CARDINAL HEALTH INC Corp BondUS14149YBJ64 | View | |
| CARDINAL HEALTH INC Corp BondUS14149YBD94 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| CARDINAL HEALTH INC Corp BondUS14149YBB39 | View |
Cardax Inc Debt to Cash Allocation
Cardax Inc currently holds 1000 K in liabilities. Cardax Inc has a current ratio of 0.09, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cardax until it has trouble settling it off, either with new capital or with free cash flow. So, Cardax's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cardax Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cardax to invest in growth at high rates of return. When we think about Cardax's use of debt, we should always consider it together with cash and equity.Cardax Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Cardax's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Cardax, which in turn will lower the firm's financial flexibility.Cardax Corporate Bonds Issued
Most Cardax bonds can be classified according to their maturity, which is the date when Cardax Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About Cardax Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Cardax prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cardax shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Cardax. By using and applying Cardax Pink Sheet analysis, traders can create a robust methodology for identifying Cardax entry and exit points for their positions.
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Cardax to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
| All Next | Launch Module |
Complementary Tools for Cardax Pink Sheet analysis
When running Cardax's price analysis, check to measure Cardax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardax is operating at the current time. Most of Cardax's value examination focuses on studying past and present price action to predict the probability of Cardax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardax's price. Additionally, you may evaluate how the addition of Cardax to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |